Medical devices, healthcare technology and the business of care
PMA approval · P150038

EXABLATE

Insightec · Decision date Jul 11, 2016

FDA DECISIONP150038

What did the FDA approve?

FDA records P150038 as an original PMA application. The recorded decision is approval, dated Jul 11, 2016.

FDA approval order statement

Approval for the ExAblate Model 4000 Type 1.0 System (ExAblate Neuro). This device is indicated for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22. The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the ExAblate device.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Jul 11, 2016

FDA source record

Regulatory record facts

Identifier
P150038
Regulatory pathway
Premarket approval application
Applicant
Insightec
Product code
POH
Decision code
APPR
Decision date
Jul 11, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: MR-guided focused ultrasound system.

Applicant
Insightec
Product code
POH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150038 received

    Application receipt date recorded by FDA.

  2. P150038 · FDA decision

    APPR

  3. P150038/S043 · Related supplement

    Exablate Model 4000 System

  4. P150038/S042 · Related supplement

    Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)

  5. P150038/S044 · Related supplement

    Exablate Model 4000 System

Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150038

Product / regulatory recordCompanyPathwayDecision dateSource
InsightecPMA supplementJan 28, 2026FDA
InsightecPMA supplementMar 5, 2026FDA
EXABLATEP150038/S041
InsightecPMA supplementMar 23, 2026FDA
InsightecPMA supplementSep 16, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Insightec

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5 Nahum Heth St., Tirat Carmel, 39120

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records